Study design
The study is a single center study. The experiments were performed in a random manner with two-arm parallel groups. The results are prospective. Methods were not changed following trial commencement.
Ethical approval
After Shanxi Bethune hospital’s committee approval, consenting parturients were invited to participant in the prospective randomized study (NO. YXLL-SL-2020-017). We had obtained all subjects’ written informed consent. This study was conducted in compliance with China Good Clinical Practice (GCP) and the tenets of the Declaration of Helsinki. Written informed consent was obtained from all parturients.We registered the study before patient enrollment at the Chinese Clinical Trial Register, a participant in the World Health Organization International Clinical Trials Registry Platform (registration number: ChiCTR2000037940, Principal investigator: Zhong-biao Nie, Registration date: 04/09/2020, URL: http://www.chictr.org.cn/edit.aspx? pid=60429&htm=4).
Patient population
Inclusion criteria were: First delivery women in the Shanxi Bethune hospital, age between 18 and 40 years, cesarean section, BMI 18 to 28 kg/m2, American Society of Anesthesiologists (ASA) grade I to II, no smoking history, opioid-naive adults.
The exclusion criteria were: parturients with severe heart, lung, liver, and kidney insufficiency, hypertension during pregnancy and preoperative fetal distress, as well as those with a history of mental or neurological diseases and opioid allergies; Opioid-tolerant parturients; the smoking history of; a history of motion sickness History; History of PONV.
Postoperative exclusion criteria: re-operation exploration, hemodynamic instability, which included serious arrhythmia, bleeding, as well as postoperative confusion. (Hemodynamic instability: SBP<90mmhg).
Anesthesia and PCA regimen
All parturients received 500mL of intravenous Lactated Ringer’s solution before epidural analgesia. The needle-through-needle technique was adopted to conduct CSEA on all participants at L3-4 or L2-3 space. When patients showed hypotension (SBP <90 mmHg or the reduction>20% of the basal SBP), they would receive 50μg of phenylephrine through intravenous injection, with fluid infusion accelerated. When SBP >180 mmHg, they would receive 25 mg of urapidil or 0.1 mg of nicardipine through intravenous injection at a lowed speed. When HR<50 bpm, they would receive 0.2 mg of atropine through intravenous injection. Following surgery, parturients would be sent to post-anesthesia care units (PACU). With stable vital signs and sensory block≤T8, parturients would be sent back to wards, connected with the PCIA pumps. PCIA pumps were stopped 36 h later.
According to body weight, 2μg/kg sufentanil (Yichang Humanwell Pharmaceutical) was diluted to 100ml with normal saline. 60 Parturients had a PCIA analgesia protocol initiated consisting of a 0.5mL bolus, and compared 2 Groups: no background infusion, 6 min lockout time (Group A). 2 mL/h infusion, 10 min lockout time (Group B). A excel ‘Random’ function-generated randomization sheet was used to prepare sealed opaque envelopes. Qualified clinical research pharmacist who took charge of drug management kept the randomized sheet; prior to surgery, drugs were placed in a sealed opaque envelope, which could only be opened by a relevant anesthesiologist who took charge of managing anesthesia and PCIA setting following protocol in the operating room. Other investigators responsible for study endpoints assessment in PACU and ward after operation knew nothing about how groups were assigned. Parturients only labeled with the study number of patients could use all PCIA devices, therefore, both the parturients and medical care providers as well as investigators cannot recognize the PCIA regimen.
The parturients were instructed on the use of the PCIA pump and told them to press the button whenever they feel pain. Parturients were allowed to receive 100 mg tramadol via intramuscular injection when they complained of pain >7 on VAS, and it was allowed to repeat the injection in necessity. The parturients were allowed to receive 10 mg of intravenous metoclopramide as a rescue antiemetic as required. If patients still presented serious nausea persisted after being administered with two consecutive rescue antiemetics, PCIA would be interrupted for two hours and be restarted when serious nausea gradually vanished.
Evaluation of outcomes
The total amount of sufentanil consumed and the two pain categories was assessed, with scores of wound pain at rest (VAS-R) scores, and uterine cramping pain (VAS-U) in the first 36 postoperative hours being the major result measurement indexes. A 10-cm visual analog scale (VAS) was used to record the pain intensity, in the range of 0 (no pain) to 10 (the worst pain imaginable). Secondary outcomes were the Ramsey sedation score (RSS) [35], assessed at the same time points, postpartum hemorrhage within 24 h. Injection/attempt (I/A) ratio. The I/A ratio was used to compare the number of the actual analgesic doses and that of the requested analgesic (attempts). In ideal conditions, the closer the I/A ratios get to 1 the better, which indicated that every patient injection should correspond to one attempt for injecting analgesic. A 4-point verbal scale was employed to rate the postoperative nausea and vomiting (PONV) (none, mild, moderate and severe respectively meaning no nausea, nausea but no vomiting, vomiting one attack and vomiting > one attack). All other side effects associated with sufentanil were dizziness, headache, constipation and pruritus. The situation of respiratory rate less than ten per min or oxygen saturation less than 90% for over 1 min is defined as respiratory depression [36]. A scale was adopted to measure the satisfaction of parturients with the PCIA for the past 36 hours, (0 = not satisfied, and 5 = very satisfied). A trained nurse blinded to how the groups were assigned took charge of assessing the parturients. Heart rate and MAP were recorded postoperatively at 6, 12, 24, and 36hours.
Statistics
The primary endpoint pain level assessed by VAS was analyzed. The expected standard deviation of means was 6.9mm, and standard deviation of subjects was 20mm. The significance level was set at 0.05 and the power at 0.8. Then sample size assumption was made through the software program PASS 11 (NCSS, LLC, Kaysville, Utah, USA) based on one-way ANOVA. And the calculated sample size was 30 in each group[28]. The SPSS software (version 20.0; IBM, USA) was applied to the statistical analyses. Measurement data are in the form of means ± standard deviations (M ± SD) or the mean difference with 95% confidence interval [MD, 95% CI]. Categorical data are in the form of frequency and cases. Whether data were in line with a normal distribution was tested via the Kolmogorov-Smirnov test. Demographic and outcome data are summarized as M ± SD. Measurement data in line with the normal distribution were compared, including VAS pain scores, I/A. The independent t test served for examining the total sufentanil consumption, satisfaction, postpartum hemorrhage. The χ2 test or Fisher’s exact test served for examining categorical data including the incidence of side effects. P values <0.05 exhibited statistical significance.